So far, full clinical brain scans on Koios users show changes in brain activity in three main areas, all of which indicate improved cognitive function.
“The findings, although preliminary, are better than we could have expected,” said Chris Miller, CEO of the Company. “Changes in the type of brain activity that we are seeing between the baseline that was mapped at the start of the study, and the effect on participants after several months of consuming our beverages, could have many positive implications.”
The study is being conducted by NeuraPerformance/Neuroptimize Brain Center, the go-to brain lab and physiotherapy clinic for Colorado’s elite athletes, including the Denver Broncos football team. The lab’s brain mapping technique involves using sensors to measure the electrical activity within the client’s brain.
The lab reported three initial findings of significance: a decrease in slow brain-wave activity, (delta and theta) which for many people “can lead to quicker thought processes, better energy, sharper focus and an overall sense of mind clarity,” says Rachel Ragsdale, founder and CEO of Neuroptimize.
The second key finding was an increase in alpha activity, linked with overall intelligence. The third finding was an increase in fast activity (beta and high beta). “This brain wave is needed to feel alert, focused, and motivated,” said Ragsdale, an accredited Board Certified Neurofeedback Therapist. “Seeing an increase in this brain wave could have many implications relating to the overall drive and energy of a person that might lack beta and is a very positive finding.”
NeuraPerformance/Neuroptimize is expected to release a full report within the next month, after which it will begin further testing the Company’s proprietary nootropic formula with CBDs. This will make Koios one of the first, if not the first, beverage company to run tests on its cannabis-infused nootropic beverages, which it is developing under its Cannavated subsidiary for the legal medical and recreational marijuana market.
Koios is a leading innovator in the nootropic beverage industry, making functional beverages that are augmented with nutrients and/or supplements to convey a health benefit to the consumer.
About the Company’s Business
The Company, through its wholly-owned subsidiary Koios, Inc., is an emerging functional beverage company which has a large and growing distribution network of retail locations across the United States in which to sell its products. Koios has relationships with some of the largest and most reputable distributors in the United States, including Europa Sports, SportLife Distribution, KeHE, and Wishing-U-Well. Together these distributors represent more than 80,000 brick-and-mortar locations across the United States – from sports nutrition stores to large natural grocery chains including Whole Foods and Sunflower markets. Through its partnership with Wishing-U-Well, Koios also enjoys a large presence online, including being an Amazon choice product.
Koios uses a proprietary blend of nootropics and natural organic compounds to enhance human productivity without using harmful chemicals or stimulants. Koios products can enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity. Its ingredients are specifically designed to target brain function by increasing blood flow, oxygen levels and neural connections in the brain.
Koios recently launched a wholly owned subsidiary, Cannavated Beverages Co. to develop a line of cannabis infused, brain-healthy drinks for the legal marijuana market.
Koios is one of the only drinks in the world to infuse its products with MCT oil. MCT oil is derived from coconuts and has been shown to help the body burn fat more effectively, create lasting energy from a natural food source, produce ketones in the brain, allowing for greater brain function and clarity, support healthy hormone production and improve immunity. For more information, please visit our website: https://www.mentaltitan.com/
On behalf of the Board of Directors of the Company.
KOIOS BEVERAGE CORP.
Chris Miller, CEO and Director
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding the timing for resumption of trading for the Company’s stock. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
Koios has not conducted any scientific studies on the effects of Koios’s products which have been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking Koios’s products will vary from person to person. No claims or guarantees can be made as to the effects of Koios’s products on an individual’s health and wellbeing.
For further information: Paula Arab, Media and Investor Relations Strategist, firstname.lastname@example.org, 403-889-9128